Molecular remission uncoupled with complete haematological response in polycythaemia vera treatment with ropeginterferon alfa‐2b.

The article discusses the treatment of polycythaemia vera (PV) with ropeginterferon alfa-2b, focusing on the molecular remission and complete haematological response achieved in patients. The study enrolled 49 patients in China, all carrying the JAK2V617F mutation, and demonstrated a significant reduction in JAK2V617F allele burden over 24 months of treatment. Ropeg treatment at a higher initiating dose regimen showed strong anti-neoplastic effects, leading to durable complete molecular remission and favourable safety outcomes in patients with PV. The study was conducted ethically and with patient consent, with data availability upon request. [Extracted from the article]